These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 27071986

  • 1. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
    Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP.
    Ann Clin Microbiol Antimicrob; 2016 Apr 12; 15():22. PubMed ID: 27071986
    [Abstract] [Full Text] [Related]

  • 2. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group.
    N Engl J Med; 2011 Feb 03; 364(5):422-31. PubMed ID: 21288078
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
    Chilton CH, Crowther GS, Todhunter SL, Ashwin H, Longshaw CM, Karas A, Wilcox MH.
    J Antimicrob Chemother; 2015 Sep 03; 70(9):2598-607. PubMed ID: 26078392
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
    Freeman J, Marquis M, Crowther GS, Todhunter SL, Fawley WN, Chilton CH, Moeck G, Lehoux D, Wilcox MH.
    J Antimicrob Chemother; 2012 Dec 03; 67(12):2919-26. PubMed ID: 22899803
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL.
    Clin Infect Dis; 2012 Aug 03; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB, Czosnowski QA.
    Ann Pharmacother; 2012 Feb 03; 46(2):219-28. PubMed ID: 22318930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.